CldU sensitizes BRCA2 reverse-mutated cells to PARP inhibitors
{{output}}
PARP inhibitors are widely used class of drugs for the treatment of homologous recombination deficient cancers, including BRCA mutated ones. These drugs led to substantial improvement in survival, particularly for patients with BRCA mutated tumors. However, ma... ...
